Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer

Breast Cancer Research

Volumn 14, Issue 5, 2012, Pages

  Bennani Baiti, Idriss M ^a  

^a RefGD   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BENZAMIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; EUTONYL TEN; HISTONE DEMETHYLASE; HISTONE H3; LETROZOLE; LOPAC P 8013; N [3 [3 (2 AMINOCYCLOPROPYL)PHENOXY] 1 (BENZYLCARBAMOYL)PROPYL]BENZAMIDE; PARGYLINE; PROTEIN LSD1; PROTEIN PELP1; SUPIRDYL; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANYLCYPROMINE; UNCLASSIFIED DRUG; COREPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; DRUG TARGETING; EDITORIAL; EPIGENETICS; GENE TARGETING; HISTONE METHYLATION; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOGENE NEU; PARACRINE SIGNALING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; BREAST TUMOR; FEMALE; GENETICS; METABOLISM;

ANIMALS; BREAST NEOPLASMS; CO-REPRESSOR PROTEINS; FEMALE; HISTONE DEMETHYLASES; HUMANS; TRANSCRIPTION FACTORS;

EID: 84866406289     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3249     Document Type: Editorial

References (18)

1. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 2012, 14:R108. 10.1186/bcr3229, 22812534.
2. Bennani-Baiti B, Bennani-Baiti IM. Gene symbol precision. Gene 2012, 491:103-109. 10.1016/j.gene.2011.09.035, 22019431.
3. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008, 319:202-206. 10.1126/science.1147674, 18187655.
4. Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK. PELP1 - a novel estrogen receptor-interacting protein. Mol Cell Endocrinol 2008, 290:2-7. 10.1016/j.mce.2008.04.019, 2578818, 18571832.
5. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schule R, Brann DW, Tekmal RR, Vadlamudi RK. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 2010, 11:438-444. 10.1038/embor.2010.62, 2892318, 20448663.
6. Rajhans R, Nair HB, Nair SS, Cortez V, Ikuko K, Kirma NB, Zhou D, Holden AE, Brann DW, Chen S, Tekmal RR, Vadlamudi RK. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol 2008, 22:649-664. 2262166, 18079323.
7. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006, 66:5504-5511. 10.1158/0008-5472.CAN-05-4076, 16707480.
8. Bennani-Baiti IM. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics 2011, 3:715-732. 10.2217/epi.11.93, 22126291.
9. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 2012, 43:1300-1307. 10.1016/j.humpath.2011.10.010, 22245111.
10. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009, 131:17536-17537. 10.1021/ja907055q, 19950987.
11. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 2004, 89:6130-6138. 10.1210/jc.2004-0909, 1262662, 15579769.
12. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 2011, 17:2250-2259. 10.1158/1078-0432.CCR-10-2718, 21421858.
13. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol Endocrinol 2012, 26:550-561. 10.1210/me.2011-1101, 22403175.
14. Kefalopoulou Z, Tzelepi V, Zolota V, Grivas PD, Christopoulos C, Kalofonos H, Maraziotis T, Sotiropoulou-Bonikou G. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. J Neurooncol 2012, 106:23-31. 10.1007/s11060-011-0637-y, 21735116.
15. Carroll RS, Zhang J, Dashner K, Sar M, Black PM. Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 1995, 37:496-503. discussion 503-494, 10.1227/00006123-199509000-00019, 7501116.
16. Mong JA, Blutstein T. Estradiol modulation of astrocytic form and function: implications for hormonal control of synaptic communication. Neuroscience 2006, 138:967-975. 10.1016/j.neuroscience.2005.10.017, 16326016.
17. Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol 2011, 13:894-903. 10.1093/neuonc/nor049, 3145466, 21653597.
18. Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schüle R, Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer 2012,